Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26704680 | 0.77 | NOS3 (0.34) | IKBKBESR1NOS3NOS1NOS2 | |
| SCHEMBL19501382 | 0.75 | BCHE (0.43) | HDAC1HDAC6BCHEACHEMAT2A | |
| SCHEMBL12120833 | 0.72 | BRD4 (0.46) | IKBKB | |
| SCHEMBL12120835 | 0.70 | BRD4 (0.36) | IKBKBESR1NOS3NOS1NOS2 | |
| SCHEMBL12120830 | 0.67 | FABP3 (0.41) | IKBKBESR1NOS3NOS1NOS2 | |
| SCHEMBL12120834 | 0.67 | MRGPRX4 (0.37) | IKBKBESR1NOS3NOS1NOS2 | |
| SCHEMBL26704683 | 0.67 | NOS3 (0.40) | ESR1NOS3NOS1NOS2 | |
| SCHEMBL12120832 | 0.66 | NOS2 (0.42) | IKBKBESR1NOS3NOS1NOS2 | |
| SCHEMBL12120831 | 0.62 | NOS3 (0.39) | ESR1NOS3NOS1NOS2 | |
| SCHEMBL1425448 | 0.62 | ALDH1A1 (0.36) | IKBKBESR1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | HDAC1 378/4885HDAC6 121/4885BCHE 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.